MedTrace Logo

Autologous Bone Marrow Stem Cell Therapy for Autism

NCT02627131 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-12-10

No results posted yet for this study

Summary

The aim of this study was to evaluate the safety and effectiveness of autologous bone marrow mononuclear stem cells in the management of autism.

Conditions

  • Autistic Disorder

Interventions

BIOLOGICAL

Autologous Bone Marrow Mononuclear Cells

Transplantation of Autologous Bone Marrow Mononuclear Cells

Sponsors & Collaborators

  • Vinmec Healthcare System

    lead OTHER

Principal Investigators

  • Liem T Nguyen, MD., PhD. · Vinmec Healthcare System

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02627131 on ClinicalTrials.gov